PHARMACOGENOMICS TEST TO BETTER TREAT … · PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS T: ......
2
PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS T: 908-222-0533 | 844-4admera admerahealth.com [ ] 50 Genes • Genetic variants affect drug absorption, metabolism and activity. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing. • Provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac and pain medications • Cutting-edge Next Generation Sequencing (NGS) technology enables comprehensive coverage of ~200 genetic variants in 50 genes. • Delivers medically actionable recommendations in an easy to interpret report. Cardiology ACE Inhibitors Angiotensin II Receptor Blockers (ARBs) Antianginal Agent Antiarrhythmic Agent Anticoagulant Antiplatelet Beta Blockers Calcium Channel Blockers Diuretics Phosphodiesterase Inhibitors Antilipemic Agent(statins) Vasodilators Infectious Diseases Antibiotics Antimalarial Drugs Antiviral Drugs Protease Inhibitors Neurology Anticonvulsant Drugs Barbiturates COMT Inhibitors Monoamine Depletors Antimigraine Agent Oncology Taxane Derivative Antimetabolite Platinum Analog Alkylating Agent Anthracycline Chemotherapy Modulating Agent Urate-Oxidase Estrogen Receptor Modulator Kinase Inhibitor Antiemetic Topoisomerase Inhibitors Immunomodulators Vinca Alkaloids Psychiatry Aldehyde Dehydrogenase Inhibitors Antianxiety Agents Antidepressants Antimanic Agents Antipsychotics Benzodiazepines Tricyclic Antidepressants Cannabinoids SNRIs SSRIs Stimulants Pain Management Anesthetics Central α-2 Adrenergic Agonists Alpha2-Adrenergic Agonist NSAIDs Opioids Opioids Antagonists Serotonin Receptor Agonists Skeletal Muscle Relaxant PGxOne™ Plus is a pharmacogenomics test that can help predict how a patient will respond to drug therapy based on individual genetic makeup. Selected Covered Drug Classes from Major Therapeutic Areas Associated drugs carry pharmacogenomics recommendations put forth by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and/or related pharmacogenomics publications.
Transcript of PHARMACOGENOMICS TEST TO BETTER TREAT … · PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS T: ......
PHARMACOGENOMICS TEST TO BETTER TREAT PATIENTS
T: 908-222-0533 | 844-4admera
admerahealth.com
[ ]50Genes
• Genetic variants affect drug absorption, metabolism and activity. Results guide effective treatment decisions, potentially reducing adverse drug events (ADEs) and trial-and-error drug selection and dosing.
• Provides recommendations for over 300 commercial drugs, with extensive coverage of psychiatric, cardiac and pain medications
• Cutting-edge Next Generation Sequencing (NGS) technology enables comprehensive coverage of ~200 genetic variants in 50 genes.
• Delivers medically actionable recommendations in an easy to interpret report.
CardiologyACE InhibitorsAngiotensin II Receptor Blockers (ARBs)Antianginal AgentAntiarrhythmic AgentAnticoagulantAntiplateletBeta BlockersCalcium Channel BlockersDiureticsPhosphodiesterase InhibitorsAntilipemic Agent(statins)Vasodilators
Infectious Diseases
AntibioticsAntimalarial DrugsAntiviral DrugsProtease Inhibitors
NeurologyAnticonvulsant Drugs
Barbiturates
COMT Inhibitors
Monoamine Depletors
Antimigraine Agent
OncologyTaxane DerivativeAntimetabolite Platinum AnalogAlkylating AgentAnthracyclineChemotherapy Modulating AgentUrate-OxidaseEstrogen Receptor Modulator Kinase InhibitorAntiemetic Topoisomerase InhibitorsImmunomodulatorsVinca Alkaloids
PsychiatryAldehyde Dehydrogenase Inhibitors Antianxiety AgentsAntidepressantsAntimanic AgentsAntipsychotics Benzodiazepines Tricyclic AntidepressantsCannabinoids SNRIs SSRIsStimulants
Pain ManagementAnestheticsCentral α-2 Adrenergic AgonistsAlpha2-Adrenergic AgonistNSAIDsOpioidsOpioids Antagonists Serotonin Receptor Agonists
Skeletal Muscle Relaxant
PGxOne™ Plus is a pharmacogenomics test that can help predict how a patient will respond to drug therapy based on individual genetic makeup.
Selected Covered Drug Classes from Major Therapeutic Areas
Associated drugs carry pharmacogenomics recommendations put forth by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and/or related pharmacogenomics publications.
T: 90
8-222-0
533 | 84
4-4admera
admerahealth
.com
*PGxOneTM Plus is the most comprehensive, commercially available pharmacogenomics test covering more genes than competitors.
PGxO
ne™ Plus provides com
prehensive coverage for major therapeutic areas.
50
G
en
es
[]
Target Genes and Select Therapeutic Areas
